Cell transplantation-mediated dystrophin supplementation efficacy in Duchenne muscular dystrophy mouse motor function improvement demonstrated by enhanced skeletal muscle fatigue tolerance.

Publisher: BioMed Central Country of Publication: England NLM ID: 101527581 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-6512 (Electronic) Linking ISSN: 17576512 NLM ISO Abbreviation: Stem Cell Res Ther Subsets: MEDLINE

Original Publication: London : BioMed Central

Muscular Dystrophy, Duchenne*/therapy ; Muscular Dystrophy, Duchenne*/genetics ; Muscular Dystrophy, Duchenne*/metabolism ; Muscular Dystrophy, Duchenne*/pathology ; Dystrophin*/genetics ; Dystrophin*/metabolism ; Muscle, Skeletal*/metabolism ; Muscle Fatigue* ; Disease Models, Animal*; Animals ; Mice ; Humans ; Myoblasts/metabolism ; Mice, Inbred mdx ; Male ; Muscle Contraction ; Cell Transplantation/methods

Background: Duchenne muscular dystrophy (DMD) is an incurable neuromuscular disease leading to progressive skeletal muscle weakness and fatigue. Cell transplantation in murine models has shown promise in supplementing the lack of the dystrophin protein in DMD muscles. However, the establishment of novel, long-term, relevant methods is needed to assess its efficiency on the DMD motor function. By applying newly developed methods, this study aimed to evaluate the functional and molecular effects of cell therapy-mediated dystrophin supplementation on DMD muscles.
Methods: Dystrophin was supplemented in the gastrocnemius of a 5-week-old immunodeficient DMD mouse model (Dmd-null/NSG) by intramuscular xenotransplantation of healthy human immortalized myoblasts (Hu5/KD3). A long-term time-course comparative study was conducted between wild-type, untreated DMD, and dystrophin supplemented-DMD mouse muscle functions and histology. A novel GO-ATeam2 transgenic DMD mouse model was also generated to assess in vivo real-time ATP levels in gastrocnemius muscles during repeated contractions.
Results: We found that 10.6% dystrophin supplementation in DMD muscles was sufficient to prevent low values of gastrocnemius maximal isometric contraction torque (MCT) at rest, while muscle fatigue tolerance, assessed by MCT decline after treadmill running, was fully ameliorated in 21-week-old transplanted mice. None of the dystrophin-supplemented fibers were positive for muscle damage markers after treadmill running, with 85.4% demonstrating the utilization of oxidative metabolism. Furthermore, ATP levels in response to repeated muscle contractions tended to improve, and mitochondrial activity was significantly enhanced in dystrophin supplemented-fibers.
Conclusions: Cell therapy-mediated dystrophin supplementation efficiently improved DMD muscle functions, as evaluated using newly developed evaluation methods. The enhanced muscle fatigue tolerance in 21-week-old mice was associated with the preferential regeneration of damage-resistant and oxidative fibers, highlighting increased mitochondrial activity, after cell transplantation. These findings significantly contribute to a more in-depth understanding of DMD pathogenesis.
(© 2024. The Author(s).)

Neuromuscul Disord. 2022 Apr;32(4):347-357. (PMID: 35339342)
Hum Mol Genet. 2015 Aug 1;24(15):4225-37. (PMID: 25935000)
Gene Ther. 2011 Sep;18(9):857-66. (PMID: 21490680)
Neurotoxicol Teratol. 2003 Sep-Oct;25(5):543-53. (PMID: 12972067)
PLoS One. 2014 Dec 26;9(12):e115763. (PMID: 25541951)
Cell Rep. 2019 Sep 10;28(11):2923-2938.e8. (PMID: 31509752)
Lancet Neurol. 2018 Mar;17(3):251-267. (PMID: 29395989)
Development. 2002 Jun;129(12):2987-95. (PMID: 12050145)
Stem Cell Reports. 2021 Dec 14;16(12):2900-2912. (PMID: 34798067)
Cell Stem Cell. 2007 Dec 13;1(6):646-57. (PMID: 18371406)
Lancet. 2019 Nov 30;394(10213):2025-2038. (PMID: 31789220)
J Exerc Rehabil. 2014 Dec 31;10(6):344-8. (PMID: 25610817)
Wiley Interdiscip Rev Syst Biol Med. 2020 Jan;12(1):e1462. (PMID: 31407867)
Pediatrics. 2018 Oct;142(Suppl 2):S34-S42. (PMID: 30275247)
Nature. 1989 Mar 16;338(6212):259-62. (PMID: 2493582)
PLoS One. 2011;6(11):e26963. (PMID: 22132085)
Hum Mol Genet. 2013 Jan 1;22(1):153-67. (PMID: 23049075)
Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H1983-9. (PMID: 21490325)
Hum Mutat. 2015 Apr;36(4):395-402. (PMID: 25604253)
J Neuromuscul Dis. 2023;10(3):439-447. (PMID: 37005891)
Stem Cell Rev Rep. 2024 Jan;20(1):138-158. (PMID: 37955832)
Dis Model Mech. 2015 Mar;8(3):195-213. (PMID: 25740330)
Eur J Pharmacol. 2023 May 15;947:175675. (PMID: 36963652)
Muscle Nerve. 2022 Sep;66(3):262-269. (PMID: 35715998)
ACS Chem Biol. 2011 Jul 15;6(7):709-15. (PMID: 21488691)
Exp Neurol. 2020 Jan;323:113086. (PMID: 31639376)
Stem Cell Rev Rep. 2018 Apr;14(2):189-199. (PMID: 29305755)
PLoS One. 2012;7(2):e31937. (PMID: 22359642)
Muscle Nerve. 2021 Sep;64(3):285-292. (PMID: 34105177)
Compr Physiol. 2015 Jul 1;5(3):1223-39. (PMID: 26140716)
Cochrane Database Syst Rev. 2016 May 05;(5):CD003725. (PMID: 27149418)
Lancet Neurol. 2022 Sep;21(9):814-829. (PMID: 35850122)
Biol Res. 2020 May 19;53(1):22. (PMID: 32430065)
Neuromuscul Disord. 2010 Dec;20(12):810-6. (PMID: 20817455)
J Clin Invest. 1999 Aug;104(4):375-81. (PMID: 10449429)
Cell. 2008 Jul 11;134(1):37-47. (PMID: 18614009)
Exp Physiol. 2011 May;96(5):539-47. (PMID: 21317219)
J Neurol. 2023 Aug;270(8):3733-3749. (PMID: 37258941)
Commun Biol. 2023 Mar 17;6(1):278. (PMID: 36932133)
Cell Rep. 2023 May 30;42(5):112434. (PMID: 37097817)
Cell. 1987 Dec 24;51(6):919-28. (PMID: 3319190)
Mol Ther. 2011 Jan;19(1):165-71. (PMID: 20924363)
Cell Stem Cell. 2012 May 4;10(5):610-9. (PMID: 22560081)
Antioxidants (Basel). 2021 Apr 03;10(4):. (PMID: 33916762)
Stem Cell Reports. 2020 Jul 14;15(1):80-94. (PMID: 32619494)
Orphanet J Rare Dis. 2020 Jun 5;15(1):141. (PMID: 32503598)
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):149-55. (PMID: 25733532)
Acta Neuropathol Commun. 2023 Oct 19;11(1):167. (PMID: 37858263)
Cell. 1988 Feb 26;52(4):503-13. (PMID: 3342447)
Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):511-7. (PMID: 20616711)
Physiol Rev. 2011 Oct;91(4):1447-531. (PMID: 22013216)
Wiley Interdiscip Rev Dev Biol. 2016 Jul;5(4):518-34. (PMID: 27199166)
Front Cell Dev Biol. 2023 Jul 11;11:1167762. (PMID: 37497476)
Muscle Nerve. 2010 Apr;41(4):500-10. (PMID: 19941337)
Mol Ther. 2018 Apr 4;26(4):1093-1108. (PMID: 29503200)
Thorax. 2022 Aug;77(8):743-744. (PMID: 35470244)
Stem Cell Rev Rep. 2022 Dec;18(8):2872-2892. (PMID: 35590083)
J Neuromuscul Dis. 2015 Nov 22;2(4):325-342. (PMID: 27858750)
Sci Transl Med. 2011 Aug 17;3(96):96ra78. (PMID: 21849666)
Med Hypotheses. 2015 Dec;85(6):1021-33. (PMID: 26365249)
J Biochem. 1995 Nov;118(5):959-64. (PMID: 8749313)
Int J Mol Sci. 2022 Dec 16;23(24):. (PMID: 36555721)
Biochim Biophys Acta. 2007 Feb;1772(2):108-17. (PMID: 16829057)
Muscle Nerve. 2017 Feb;55(2):243-253. (PMID: 27301985)
Neurology. 2020 May 26;94(21):e2270-e2282. (PMID: 32139505)
J Muscle Res Cell Motil. 2003;24(7):387-97. (PMID: 14677641)
J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):747-53. (PMID: 24292997)
Postepy Kardiol Interwencyjnej. 2022 Dec;18(4):399-406. (PMID: 36967847)
Biochem Biophys Res Commun. 2005 Mar 11;328(2):507-16. (PMID: 15694376)
Stem Cells Transl Med. 2021 Oct;10(10):1406-1418. (PMID: 34291884)
Skelet Muscle. 2020 Jun 3;10(1):17. (PMID: 32493438)

JP13bm0104001 Japan Agency for Medical Research and Development; JP23bm1323001 Japan Agency for Medical Research and Development; 22ama121050j0002 Japan Agency for Medical Research and Development; 20ek0610017h0003 Japan Agency for Medical Research and Development; 17J40184 Japan Society for the Promotion of Science

Keywords: Cell transplantation; Duchenne muscular dystrophy mouse model; Dystrophin supplementation; GO-ATeam2 transgenic mouse model; In vivo ATP imaging; Mitochondrial activity; Motor function evaluation; Muscle fatigue tolerance; Oxidative slow fibers

0 (Dystrophin)

Date Created: 20240919 Date Completed: 20240920 Latest Revision: 20240925

20240925

PMC11414159

10.1186/s13287-024-03922-x

39300595